Sensus Healthcare (SRTS) AI Stock Analysis

• Market Cap: $64.04M
• Dividend Yield: N/A
• Average Volume (3M): 99.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: -13.79%
• EPS Growth: -132.21%
• Country: US
• Employees: 54
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.19
• Shares Outstanding: 16,462,059
• 10 Day Avg. Volume: 103,770
• 30 Day Avg. Volume: 99,054
• PEG Ratio: 0.04
• Price to Book (P/B): 1.35
• Price to Sales (P/S): 2.36
• P/FCF Ratio: 195.73
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: 1.55
• Enterprise Value/Gross Profit: 3.59
• Enterprise Value/Ebitda: -6.35
• 1Y Price Target: $6.50
• Price Target Upside: 84.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.28
• Revenue Forecast (FY): $27.97M

• Rating: 52 Neutral
• Price Target: $4.50 ▲(27.84% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is held back primarily by weak and volatile 2025 financial performance (revenue decline, margin compression, and losses) and a negative earnings-based valuation (negative P/E). Offsetting factors include a very strong, low-debt balance sheet and a more optimistic earnings-call outlook tied to new CPT reimbursement codes and guidance for sequential improvement and a 2026 profitability target, while technical indicators remain broadly neutral.

Positive Factors

Reimbursement clarity (CPT codes)

Dedicated CPT codes create a structural reimbursement uplift (management cited ~300% per-fraction increase). Lasting reimbursement clarity improves physician economics, shortens purchase payback, underpins sustained demand and utilization, and materially reduces payor uncertainty over the 2–6 month commercialization horizon.

Strong balance sheet and liquidity

A well-capitalized balance sheet with $22.1M cash and zero debt provides durable financial flexibility to fund commercial expansion, R&D, and inventory builds without near-term refinancing. This cushions the firm through cyclical demand volatility and supports multi-quarter scaling initiatives.

Proof of concept & international traction

Rapid utilization growth in the FDA fair-deal program and international shipments demonstrate product adoption and commercial viability. Increased treatments raise recurring consumables and service revenue potential and validate international channels, supporting sustainable revenue upside as commercialization scales.

Negative Factors

Revenue and margin deterioration

A sharp revenue decline and swing to a sizable net loss indicate structural volatility in demand, pricing or customer mix. Such deterioration undermines margin sustainability and the ability to generate reliable operating cash, creating risk that near-term profitability targets may be difficult to achieve without durable demand recovery.

Customer concentration risk

Heavy prior dependence on one large customer creates outsized revenue sensitivity. Excluding that customer's contribution from forecasts raises uncertainty around baseline demand, increasing reliance on new reimbursement-driven adoption and sales hires to replace lost volumes and stabilize multi-quarter revenue.

Inventory build and inconsistent cash generation

A sizable inventory build alongside weak and inconsistent free cash flow strains working capital and ties up liquidity if system adoption lags. Elevated inventories plus prior years of negative operating cash flow increase the risk that commercialization investment will pressure margins and require external funding if growth delays persist.

Sensus Healthcare Business Overview & Revenue Model

Company Description

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

How the Company Makes Money

Sensus Healthcare generates revenue through the sale of its medical devices and systems, specifically the Sensus system, which is used for non-invasive skin cancer treatment. The company's revenue model is primarily based on direct sales to healthcare providers, including hospitals, outpatient surgical centers, and dermatology practices. In addition to device sales, Sensus Healthcare also earns revenue through recurring sales of consumables and accessories that accompany its treatment systems. Strategic partnerships with healthcare institutions and distributors enhance the company's reach and facilitate market penetration, while ongoing research and development efforts aim to expand its product offerings and improve existing technologies, contributing to future growth and revenue streams.

Sensus Healthcare Financial Statement Overview

Summary

Overall fundamentals are mixed: the balance sheet is strong with very low leverage (debt-to-equity ~1–2%), but operating results deteriorated sharply in 2025 with a major revenue decline, margin compression, and a swing from profit to a sizable net loss. Cash flow has been inconsistent, with only modestly positive operating cash flow in 2025 and materially weaker free cash flow versus 2024.

Income Statement

Results have been volatile. Revenue fell sharply in 2025 (down ~23% year over year) after growth in 2024, and profitability swung from healthy profits in 2024 (about 16% net margin) to a sizable loss in 2025 (about -28% net margin) with negative operating margins. Gross margin also compressed meaningfully in 2025 versus prior years, indicating weaker pricing, mix, or cost absorption. The main strength is that the business has previously demonstrated the ability to generate strong margins (notably 2022 and 2024), but the recent deterioration and inconsistency weigh heavily on quality.

Balance Sheet

The balance sheet appears conservatively financed, with very low leverage (debt-to-equity roughly 1–2% in recent years) and equity representing the vast majority of the capital base. This provides flexibility to absorb earnings volatility. The key weakness is that returns on equity have turned negative in 2025 due to losses (after positive returns in 2024 and very strong levels in 2022), highlighting that strong capitalization has not translated into consistent shareholder returns.

Cash Flow

Cash generation has been inconsistent. Operating cash flow was negative for multiple years (2020–2024) and turned modestly positive in 2025 (~$0.5M), but free cash flow also dropped materially in 2025 versus 2024 (down ~76%), suggesting weaker underlying cash performance despite the return to positive territory. A positive is that cash burn has not been persistent at extreme levels and 2025 shows improvement versus prior years, but the overall pattern lacks stability and does not consistently support reported profitability.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	27.48M	41.81M	24.41M	44.53M	27.04M
Gross Profit	11.87M	24.43M	14.06M	29.63M	16.99M
EBITDA	-9.92M	8.52M	79.00K	15.34M	4.73M
Net Income	-7.72M	6.65M	485.00K	24.24M	4.12M
Balance Sheet
Total Assets	53.04M	62.16M	53.71M	56.73M	32.24M
Cash, Cash Equivalents and Short-Term Investments	22.08M	22.06M	23.15M	25.52M	14.52M
Total Debt	680.00K	602.00K	783.00K	1.02M	225.00K
Total Liabilities	4.94M	6.34M	4.87M	8.67M	6.22M
Stockholders Equity	48.10M	55.83M	48.84M	48.07M	26.02M
Cash Flow
Free Cash Flow	332.00K	-1.11M	-2.37M	-1.57M	-414.00K
Operating Cash Flow	528.00K	-831.00K	-2.15M	-1.41M	-286.00K
Investing Cash Flow	-196.00K	-276.00K	-187.00K	14.84M	129.00K
Financing Cash Flow	-305.00K	15.00K	-40.00K	-2.43M	-231.00K

Sensus Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Negative. The current price of 3.52 is below the 20-day moving average (MA) of 4.09, below the 50-day MA of 4.54, and below the 200-day MA of 4.11, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 38.12 is Neutral, neither overbought nor oversold. The STOCH value of 9.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRTS.

Sensus Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HYPR	59 Neutral	$110.77M	-2.60	-103.93%	―	-20.10%	7.87%
SRTS	52 Neutral	$64.04M	-5.13	-15.11%	―	-13.79%	-132.21%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NSPR	47 Neutral	$69.91M	-3.48	-87.61%	―	14.04%	-0.65%
ICCM	45 Neutral	$47.40M	―	-243.68%	―	-18.96%	8.98%
CTSO	44 Neutral	$44.44M	-4.62	-96.15%	―	-8.97%	47.29%
RBOT	42 Neutral	$3.85M	-0.26	-181.79%	―	―	15.03%